GMHC Treatment Issues 1993 May 1; 7(5): 11
Kissei, a Japanese drug company, paid $20 million for Asian
marketing rights to Vertex's HIV protease inhibitors. Vertex
has several protease compounds in preclinical development.
Vertex claims its protease compounds are more potent than
Abbott's and more bioavailable than Roche's.
Copyright (c) 1993 - GMHC Treatment Issues. Noncommercial
reproduction encouraged. Distributed by AEGIS, your online
gateway to a world of people, knowledge, and resources. Direct
Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet:
telnet:aegis.com www: www.aegis.com